PeptideStack
5.2kquestions
20kanswers
220users

Does AST tell me anything about hepatic fat on survodutide?

Asked 7 Feb 2026Modified 3 months agoViewed 6.7k times
18

What I have: AST · survodutide.

I would like the mechanism, because I want to be able to reason about the cases nobody has written about.

I have tried to reason it out from first principles and got to two contradictory conclusions.

Can someone derive this rather than assert it?

liver-enzymes
liver-enzymes

ALT, AST, GGT and ALP: what they do and do not indicate about hepatic fat, why enzymes are a poor surrogate for histology, and where non-invasive…

91 questions
mash
mash

Metabolic dysfunction-associated steatohepatitis: histological endpoints, resolution without worsening fibrosis, fibrosis improvement by stage,…

56 questions
bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
DR
askedDr_Priya_Raghunathan49k1377 Feb 2026

5 Answers

Sorted by votes
25

This is one of the areas where the trend across several measurements is far more informative than any single result.

Alanine aminotransferase is relatively liver-specific; aspartate aminotransferase is also present in muscle, heart and red cells. A raised AST with a normal ALT after heavy resistance training is usually muscle, and creatine kinase settles the question.

Stated carefully, very rapid weight loss can transiently worsen liver biochemistry, which is one of several arguments against pursuing the steepest possible trajectory.

The caveat is direct: rising liver enzymes with jaundice, dark urine or right-upper-quadrant pain is a same-day clinical problem, not a forum question.

Get a baseline before you start anything, because it converts an uninterpretable result into an interpretable one for the cost of one blood draw.

shareimprove this answerflag
DB
answeredDr_Signe_Baldursdottir29k2711 May 2026
2Minor: haemolysis inflates potassium enough to cause a fright over what is a handling artefact. – assay_blank 10 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
18

Before attributing anything to a compound, account for alcohol, muscle injury from new training, and any over-the-counter product being taken alongside.

Reference upper limits around forty units per litre for ALT are conventional rather than physiological; several groups have argued for limits closer to thirty for men and twenty-five for women.

Worth being precise here: gamma-glutamyl transferase is sensitive and unspecific: it rises with alcohol, with several medications and with fatty liver, and an isolated elevation rarely changes anything on its own.

Hy's law and its variants are the standard framework for identifying drug-induced liver injury in trials and are why bilirubin is measured alongside transaminases rather than instead.

New training, alcohol and over-the-counter products first. Then the interesting hypotheses.

shareimprove this answerflag
DV
answeredDr_Ilse_Vandenberg113k24830 Apr 2026
2Adding a vote because this deserves more of them. – Dr_Rosalind_Achebe 7 months ago
3I would add a sentence about baseline: without one, the second panel is a snapshot rather than a trend. – Dr_Ingrid_Baumgartner 9 months ago
add a comment
12

Answer first: mild transaminase elevation is common in this population before any drug is involved, and the usual cause is hepatic steatosis rather than anything acute.

Creatine kinase, alkaline phosphatase and bilirubin together tell you which compartment the abnormality is in, and ordering the transaminases alone throws that information away.

Hy's law describes the combination that matters: transaminases above three times the upper limit together with bilirubin above twice the upper limit and no cholestatic explanation. That combination is a signal; isolated mild transaminase elevation is not.

Laboratory-specific reference intervals for transaminases vary enough that cross-laboratory comparison of borderline values is unreliable.

Attributing an enzyme change to a compound requires a baseline, and most people asking have not got one.

Isolated mild elevation is common and usually improves with weight loss.

edited 27 Apr 2026 by Dr_Idris_Coulibaly — tightened the wording; no substantive change

shareimprove this answerflag
DC
answeredDr_Idris_Coulibaly33k13719 Apr 2026
5The one-in-twenty out-of-range arithmetic should be printed at the top of every panel report. – Dr_Ravi_Selvarajah 9 months ago
add a comment
10

Stated carefully, reference intervals for alanine aminotransferase differ between laboratories and have been revised downward over time, so the same value can be normal on one report and elevated on another.

Weight loss of ten per cent or more typically reduces transaminases substantially in people whose elevation was driven by hepatic fat, which is the majority of mild elevations in this population.

Population data show a substantial fraction of adults with mild transaminase elevation attributable to hepatic steatosis, which sets the base rate against which any new finding should be read.

Nothing here is medical advice. An abnormal result needs somebody who can take a history and examine you.

Read the pattern before the magnitude, and the magnitude in multiples of the upper limit.

shareimprove this answerflag
DC
answeredDr_Idris_Coulibaly33k1378 Apr 2026
7

The honest answer is that mild elevation is very common, that it usually improves with weight loss, and that the exceptions are the reason anyone checks.

An isolated result three weeks after starting anything is difficult to interpret. A baseline taken before starting makes the same result trivially interpretable, which is the argument for baselines.

Trials in this class have generally reported improvement rather than deterioration in liver biochemistry, consistent with the weight-mediated mechanism.

Transaminases plus bilirubin plus alkaline phosphatase, or you have not measured enough to conclude anything.

edited 11 Mar 2026 by Dr_Ravi_Selvarajah — reworded for clarity after a comment

shareimprove this answerflag
DS
answeredDr_Ravi_Selvarajah35k13725 Feb 2026
6Thank you — separating "out of range" from "abnormal" is the distinction I needed. – plate_count_9k 12 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.